Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714072 · ClinicalTrials.gov registry record · Phase 1
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
A Phase 1 study of Myelofibrosis Due to and Following Polycythemia Vera, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT05714072: Recruiting Phase 1 study of Myelofibrosis Due to and Following Polycythemia Vera, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05714072 is a Phase 1 study of Myelofibrosis Due to and Following Polycythemia Vera that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants. The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05714072, a Phase 1 study of Myelofibrosis Due to and Following Polycythemia Vera, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Ruxolitinib
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05714072
The ClinicalTrials.gov registry entry for NCT05714072 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis Due to and Following Polycythemia Vera appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.
NCT05714072 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05714072 about?
NCT05714072 is a clinical study titled "A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis". The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
What is the current status of trial NCT05714072?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-01-25. Estimated completion is 2027-01.
What conditions does trial NCT05714072 study?
This clinical trial studies the following conditions: Myelofibrosis Due to and Following Polycythemia Vera.
What interventions are being tested in trial NCT05714072?
The interventions under investigation include: Abemaciclib (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT05714072?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714072 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis Due to and Following Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.